Ivabradine Cuts Heart Failure Mortality Rates

Ivabradine Cuts Heart Failure Mortality Rates

heart rate in cardiovascular pathophysiology

Illustration courtesy of https://www.shift-study.com

A study presented at the European Society of Cardiology (ESC) Congress 2010 gives promising results to patients suffering from heart failure with tachycardia (increased heart rate). The study, called Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial (SHIFT), provided scientists with a strong case for ivabradine’s usefulness as an adjunct agent in the treatment of chronic heart failure (CHF). The drug acts on the SA node of the heart and slows down its rapid beating, one of the discussants of the study, Dr. Anand of the University of Minnesota said. Another important implication of the results points out to the role of increased heart rate as a mediator in the disease progression of CHF.

Heart failure, characterized by the inability of the heart to cope with the blood flow needs of the body, can result from numerous abnormal conditions such as coronary artery disease, congenital heart defects and drug abuse among others. It is a debilitating and consequently deadly condition if left mismanaged in the long run. Current treatment guidelines that include the use of beta blockers have their pitfalls when used in patients who are unable to tolerate higher doses of this class of drugs. The results of the SHIFT study promises to pick up on the shortcomings of beta blockers in this area by improving the quality of life of its sufferers.

Dr. Clyde Yancy of Baylor University Medical Center, Texas expressed his lukewarm response to the results, saying that genetic differences must be taken into account before using ivabradine that is solely based on the SHIFT study. Since participants of the study were from outside US and Western Europe, he says that predicting clinical outcomes on a broader patient population is difficult which is why he encourages further studies on the drug.

ivabradine hydrochlorideLGM Pharma currently works with various educational institutions and medical centers who are actively engaged in further R&D of the drug, ivabradine. Ivabradine Hydrochloride CAS# 148849-67-6 is supplied by LGM Pharma to its clients. The company’s strict adherence to international and local regulatory standards has made it the supplier of choice for research molecules by global pharmaceutical firms.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service